These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29695782)

  • 1. Can anti-obesity drugs be repurposed to treat cocaine addiction?
    Reiner DJ; Bossert JM
    Neuropsychopharmacology; 2018 Sep; 43(10):1983-1984. PubMed ID: 29695782
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats.
    Hernandez NS; Ige KY; Mietlicki-Baase EG; Molina-Castro GC; Turner CA; Hayes MR; Schmidt HD
    Neuropsychopharmacology; 2018 Sep; 43(10):2000-2008. PubMed ID: 29497166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine.
    Schmidt HD; Mietlicki-Baase EG; Ige KY; Maurer JJ; Reiner DJ; Zimmer DJ; Van Nest DS; Guercio LA; Wimmer ME; Olivos DR; De Jonghe BC; Hayes MR
    Neuropsychopharmacology; 2016 Jun; 41(7):1917-28. PubMed ID: 26675243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.
    Finan B; Clemmensen C; Müller TD
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():42-54. PubMed ID: 26151488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 agonists.
    Padwal R
    BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials.
    Costantino S; Paneni F
    Vascul Pharmacol; 2019 Apr; 115():64-68. PubMed ID: 30926561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 10. Inactivation of NMDA Receptors in the Ventral Tegmental Area during Cocaine Self-Administration Prevents GluA1 Upregulation but with Paradoxical Increases in Cocaine-Seeking Behavior.
    Guzman D; Carreira MB; Friedman AK; Adachi M; Neve RL; Monteggia LM; Han MH; Cowan CW; Self DW
    J Neurosci; 2018 Jan; 38(3):575-585. PubMed ID: 29196318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of cholinergic transmission from the laterodorsal tegmental nucleus to the ventral tegmental area in cocaine-induced place preference.
    Shinohara F; Kihara Y; Ide S; Minami M; Kaneda K
    Neuropharmacology; 2014 Apr; 79():573-9. PubMed ID: 24467849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cocaine-reinstated drug-seeking behavior by kappa-opioid receptors in the ventral tegmental area of rats.
    Sun W; Xue Y; Huang Z; Steketee JD
    Psychopharmacology (Berl); 2010 Jun; 210(2):179-88. PubMed ID: 20232055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats.
    Antkiewicz-Michaluk L; Filip M; Michaluk J; Romańska I; Przegaliński E; Vetulani J
    J Neural Transm (Vienna); 2007 Mar; 114(3):307-17. PubMed ID: 16897599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both glutamate receptor antagonists and prefrontal cortex lesions prevent induction of cocaine sensitization and associated neuroadaptations.
    Li Y; Hu XT; Berney TG; Vartanian AJ; Stine CD; Wolf ME; White FJ
    Synapse; 1999 Dec; 34(3):169-80. PubMed ID: 10523754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic plasticity and addiction: learning mechanisms gone awry.
    Mameli M; Lüscher C
    Neuropharmacology; 2011 Dec; 61(7):1052-9. PubMed ID: 21277315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice.
    Mathon DS; Lesscher HM; Gerrits MA; Kamal A; Pintar JE; Schuller AG; Spruijt BM; Burbach JP; Smidt MP; van Ree JM; Ramakers GM
    Neuroscience; 2005; 130(2):359-67. PubMed ID: 15664692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug addiction. Zapping memory center triggers drug craving.
    Holden C
    Science; 2001 May; 292(5519):1039. PubMed ID: 11352038
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area.
    Sarti F; Borgland SL; Kharazia VN; Bonci A
    Eur J Neurosci; 2007 Aug; 26(3):749-56. PubMed ID: 17686047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1/glucagon receptor co-agonism for treatment of obesity.
    Sánchez-Garrido MA; Brandt SJ; Clemmensen C; Müller TD; DiMarchi RD; Tschöp MH
    Diabetologia; 2017 Oct; 60(10):1851-1861. PubMed ID: 28733905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.